Compare ERIC & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ERIC | ILMN |
|---|---|---|
| Founded | 1876 | 1998 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.9B | 26.7B |
| IPO Year | 2002 | 2000 |
| Metric | ERIC | ILMN |
|---|---|---|
| Price | $10.22 | $218.98 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 17 |
| Target Price | $11.00 | ★ $124.24 |
| AVG Volume (30 Days) | ★ 10.1M | 2.0M |
| Earning Date | 04-17-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.82% | N/A |
| EPS Growth | N/A | ★ 170.87 |
| EPS | N/A | ★ 2.22 |
| Revenue | N/A | ★ $4,343,000,000.00 |
| Revenue This Year | N/A | $6.47 |
| Revenue Next Year | $1.83 | $5.58 |
| P/E Ratio | ★ $12.13 | $96.05 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.71 | $88.00 |
| 52 Week High | $13.77 | $220.32 |
| Indicator | ERIC | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 49.67 | 69.38 |
| Support Level | $9.26 | $117.64 |
| Resistance Level | $10.35 | N/A |
| Average True Range (ATR) | 0.15 | 8.25 |
| MACD | 0.06 | 1.58 |
| Stochastic Oscillator | 61.54 | 95.65 |
Ericsson is a networking equipment and software provider, primarily selling mobile networking equipment and services to wireless service providers. Ericsson operates in three segments: networks, cloud software and services, and enterprise. While large wireless carriers are its largest customers, Ericsson has expanded its offerings for large enterprises. These products and services include private 5G networking, contact centers as a service, and application performance interfaces. Ericsson aims to combine its 5G network expertise with cloud-native, as-a-service platforms offering a more comprehensive hardware and software package. Ericsson also monetizes its research and development investments by licensing patents to handset manufacturers.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.